natgillin/translations-raw huggingface dataset:
BiResp Spiromax 160 микрограма/4,5 микрограма прах за инхалация
BiResp Spiromax 160 micrograms /4.5 micrograms inhalation powder
BiResp Spiromax 320 µg/9 µg прах за инхалация будезонид/формотеролов фумарат дихидрат Инхалаторно приложение
BiResp Spiromax 320 mcg/9 mcg inhalation powder budesonide/formoterol fumarate dihydrate Inhalation use.
BiResp Spiromax 320 микрограма/9,0 микрограма трябва да се използва само като поддържаща терапия.
BiResp Spiromax 320 micrograms/9 micrograms should be used as maintenance therapy only.
BiResp Spiromax budesonide/formoterol
BiResp Spiromax budesonide / formoterol
BiResp Spiromax НЕ е показан за употреба при деца на 12 години и по-малки или юноши на възраст между 13 и 17 години.
BiResp Spiromax is NOT indicated for use in children 12 years of age and younger or adolescents 13 to 17 years of age.
BiResp Spiromax НЕ е показан за употреба при деца на 12 години и по-малки или юноши на възраст между 13 и 17 години.
BiResp Spiromax is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
BiResp Spiromax е показан за употреба само при възрастни на 18 и повече години.
BiResp Spiromax is indicated for use in adults 18 years of age and older only.
BiResp Spiromax е „хибридно лекарство“.
BiResp Spiromax is a ‘hybrid medicine’.
BiResp Spiromax не е показан за употреба при деца на 12 години и по-малки или юноши на възраст 13 до 17 години.
BiResp Spiromax is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
BiResp Spiromax не е показан при деца и юноши на възраст под 18 години (вж. точка 4.2).
BiResp Spiromax is not indicated in children and adolescents under the age of 18 years (see section 4.2).
BiResp Spiromax също така се използва за облекчаване на симптомите на тежка хронична обструктивна белодробна болест (ХОББ) при възрастни, които са имали екзацербации (изостряния) на болестта в миналото въпреки редовната терапия.
BiResp Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Bishop´s Stortford CM22 6PU - UK
Bishop´s Stortford CM22 6PU – UK
Bister in brezbarven koncentrat za raztopino za infundiranje.
Clear and colourless concentrate for solution for infusion.
Bistra, bledo-rumena tekočina. pH = 2,0-2,6.
Clear pale yellow liquid. pH = 2.0-2.6.
BIVERKNINGAR
ADVERSE REACTIONS
Biverkningar
Undesirable effects
Biverkningar (frekvens och allvarlighetsgrad)
Adverse reactions (frequency and seriousness)
Biverkningarna presenteras inom varje frekvensområde efter fallande allvarlighetsgrad.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Biverkningarna är klassificerade efter frekvens och organsystemklass.
Adverse reactions are classified according to frequency and System Organ Class.
BIVIRKNINGER
ADVERSE REACTIONS
Bivirkninger (forekomst og sværhedsgrad)
Adverse reactions (frequency and seriousness)
BL HIV-1 РНК < 5.0 log 1 копия/ml
BL HIV-1 RNA < 5.0 log 1 copies/ml
BL HIV-1 РНК ≥ 5.0 log 1 копия/ml
BL HIV-1 RNA ≥ 5.0 log 1 copies/ml
bL1 протеин под формата на вирусоподобни частици, произведени върху дрождеви клетки (Saccharomyces cerevisiae CANADE 3C-5 (Щам 1895)) чрез рекомбинантна ДНК технология. cадсорбирани върху аморфен алуминиев хидроксифосфат сулфат адювант (225 микрограма Al).
b L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology c adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al)
Blackthorn Road IE - Dublin 18
IE - Dublin 18
Blaga do zmerna ledvična okvara bistveno ne vpliva na farmakokinetične parametre palonosetrona.
Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters.
Blaga do zmerna okvara ledvic (ki je določena z ocenjenim očistkom kreatinina < 60 ml/min).
Moderate to severe renal impairment (defined as an estimated creatinine clearance < 60 ml/min).
Blaga ledvična okvara (CrCl 51 do 80 ml/min)
Mild renal impairment (CrCl 51 to 80 ml/min)
Blanda försiktigt för att rekonstituera och kontrollera att innehållet är fullständigt upplöst.
Mix gently to reconstitute and check to see that the contents have dissolved completely.
Blanda försiktigt lösningen och kontrollera att innehållet lösts upp helt.
Mix gently to reconstitute and check to see that the contents have dissolved completely.
Blanda inte med något annat läkemedel förutom de som nämns under avsnitt 4.8.
Do not mix with any other veterinary medicinal product except those mentioned in section 4.8.
BLB 016 Bulebel Industrial Estate Zejtun ZTN 3 000
BLB 016 Bulebel Industrial Estate Zejtun ZTN 3000
BLB 016 Bulebel Industrial Estate Zejtun ZTN 3000
BLB016 Bulebel Industrial Estate Zejtun ZTN 3000
BLB 016 Bulebel Industrial Estate Zejtun ZTN 3000
BLB016 Bulebel Industrial Estate, Zejtun ZTN 3000
BLB 016, Bulebel Industrial Estate, Zejtun ZTN, Малта
BLB016, Bulebel Industrial Estate, Zejtun ZTN 3000, Malta
bledá barva pokožky (bledost)
pale skin colour (pallor)
BLINCYTO 38,5 микрограма прах за концентрат и разтвор за инфузионен разтвор
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.
BLINCYTO 38,5 микрограма прах за концентрат и разтвор за инфузионен разтвор блинатумомаб (blinatumomab)
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion blinatumomab
Blincyto e лекарство за рак, което се използва за лечение на възрастни пациенти с B-прекурсорна остра лимфобластна левкемия (ALL), вид рак на кръвта.
Blincyto is a cancer medicine used to treat adult patients with B-precursor acute lymphoblastic leukaemia (ALL), a type of blood cancer.
Blincyto действа като „мост“, който свързва T-клетките и B-клетките.
Blincyto acts as a ‘bridge’ to bring the T-cells and the B-cells together.
BLINCYTO е бил оценяван при педиатрични пациенти с рецидивирала или рефрактерна В-прекурсорна ОЛЛ във фаза I/II проучване за повишаване на дозата/оценка.
BLINCYTO has been evaluated in paediatric patients with relapsed or refractory B-precursor ALL in a phase I/II dose escalation/evaluation study.
BLINCYTO е показан за лечение на възрастни пациенти с рецидивирала или рефрактерна В-прекурсорна остра лимфобластна левкемия (ОЛЛ), отрицателна за Филаделфийска хромозома.
BLINCYTO is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).
BLINCYTO е прилаган като продължителна интравенозна инфузия.
BLINCYTO was administered as a continuous intravenous infusion.
Blincyto е проучен в едно основно проучване при 189 пациенти с Ph- B-клетъчна, прекурсорна ALL, при които левкемията се завръща или не се повлиява от лечението.
Blincyto has been studied in one main study in 189 patients with Ph- B-cell precursor ALL whose leukaemia had come back or had not responded to treatment.
Blincyto е разрешен за употреба по т.нар. схема „разрешаване под условие“.
Blincyto has been given ‘conditional approval’.
BLINCYTO е съвместим с полиолефин, PVC не-диетилхексилфталат (не DEHP) или етил винил ацетат (EVA) инфузионни сакове/помпени касети.
BLINCYTO is compatible with polyolefin, PVC non-di-ethylhexylphthalate (non-DEHP), or ethyl vinyl acetate (EVA) infusion bags/pump cassettes.
BLINCYTO може да не е подходящ за Вас ако: някога сте имали неврологични проблеми, например треперене (или тремор), патологични усещания, гърчове, загуба на памет, обърканост, дезориентация, нарушено равновесие или затруднен говор.
BLINCYTO may not be suitable for you: if you have ever had neurological problems, for example, shaking (or tremor), abnormal sensations, seizures, memory loss, confusion, disorientation, loss of balance, or difficulty in speaking.
BLINCYTO може да предизвика неврологични проблеми като замайване, гърчове, обърканост, нарушена координация и нарушено равновесие.
BLINCYTO can cause neurological problems such as dizziness, seizures, confusion, coordination and balance disorders.
BLINCYTO не трябва да се използва при деца и юноши на възраст под 18 години.
BLINCYTO should not be used in children and adolescents below 18 years of age.
BLINCYTO обичайно се прилага за 2 цикъла на лечение.
BLINCYTO is usually given for 2 treatment cycles.
Blincyto се използва при завръщане на ALL или при липса на отговор към предходно лечение.
Blincyto is used when the ALL has come back or has not responded to previous treatment.
Blincyto се отпуска само по лекарско предписание и лечението трябва да започне от лекар с опит в диагностицирането и лечението на пациенти с рак на кръвта.
Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Blincyto се предлага под формата на прах за приготвяне на разтвор за инфузия (вливане) във вена.
Blincyto is available as a powder that is made up into a solution for infusion (drip) into a vein.
Blincyto съдържа активното вещество блинатумомаб (blinatumomab).
Blincyto contains the active substance blinatumomab.
BLINCYTO трябва да се влива чрез специален отвор.
BLINCYTO should be infused through a dedicated lumen.
BLINCYTO ще се прилага чрез вена (интравенозно) непрекъснато за 4 седмици, с помощта на инфузионна помпа (това е 1 ят цикъл на лечение).
BLINCYTO will be given to you through a vein (intravenous) continuously for 4 weeks using an infusion pump (this is 1 treatment cycle).
blister
(PVC/alu)
blister
Alu)
blister (PA/Alu/PVC – Alu)
Alu) blister (PA/Alu/PVC – Alu)
blister (PA/Alu/PVC – Alu)
blister (PA/Alu/PVC
Blister av polyklortrifluoreten (PCTFE)/polyeten (PE)/polyvinylklorid (PVC)/aluminium.
Blisters made of polychlorotrifluorethylene (PCTFE) / polyethylene (PE) / polyvinylchloride (PVC) / aluminium.
Blisterpakning
Blister pack
blistr (PVC/Al)
blister (PVC/alu)
Blistr sestává ze 2 vrstev, průhledné, tepelně tvarovatelné pevné fólie laminované PCTFE k PVC vrstvě, ke které přiléhá protlačovací hliníková fólie.
The blister strips comprise of 2 layers, a clear thermoformable rigid film which is laminated with PCTFE to a PVC backing to which a push-through aluminium foil is adhered.
BLISTR/krabička po 4 x 1, 30 x 1 nebo 100 x 1 tabletách
BLISTER / Box of 4x1, 30x1 or 100x1 tablets
BLISTR/krabičky o 30, 50x1, 90 nebo 100 tabletách
BLISTER/Boxes of 30, 50x1, 90 or 100 tablets
BLISTRY
BLISTERS
Blistry jsou umístěny v kartónových krabičkách.
The blisters are contained in cardboard cartons.
Block 2, International Science Centre, National Technology Park Castletroy
Block 2, International Science Centre, National Technology Park Castletroy, Limerick
Blodbrist (anemi)
Anaemia
Blodet och
Blood and
Blodet och lymfsystemet:
Blood and lymphatic system disorders:
Blodkärl Flebit
Blood creatinine increased
Blodnivåerna som uppmättes efter intag av en Emtriva 200 mg hård kapsel liknar de som uppmättes efter intag av 24 ml av den orala lösningen.
The blood levels obtained after taking one Emtriva 200 mg hard capsule are similar to those obtained after taking 24 ml of the oral solution.
blodnje*,
Delusion
blodnje,
Delusion
Blokátory kalciového kanálu
cobicistat.
Blue кръгли и двойно изпъкнали таблетки от 6,1 мм в, гравирани с надпис "5" от едната страна.
Blue round and biconvex tablets of 6.1 mm in diameter, engraved with “5” on one side
Bluevac BTV8 е одобрен при „извънредни обстоятелства“.
Bluevac BTV8 has been authorised under ‘exceptional circumstances’.
BLUEVAC BTV8 инжекционна суспензия за говеда и овце
BLUEVAC BTV8 suspension for injection for cattle and sheep
Bluevac BTV8 се използва за активна имунизация на говеда и овце срещу вируса на болестта син език.
Bluevac BTV8 is used in cattle and sheep for the active immunisation against bluetongue virus disease.
BLUEVAC BTV8 стимулира активния имунитет срещу вируса на болестта син език, серотип 8
BLUEVAC BTV8 stimulates active immunity against bluetongue virus, serotype 8.
Bluevac BTV8 съдържа един тип вируси на син език („серотип 8“).
Bluevac BTV8 contains bluetongue viruses of one type (‘serotype 8’).
BN {nummer}
BN {number}
BN {nummer}:
BN{number}
BO17707 е многоцентрово фаза III, рандомизирано, контролирано, открито клинично проучване с две групи, сравняващо ефекта от добавяне на Avastin към карбоплатин плюс паклитаксел при пациенти след операция на епителен карцином на яйчниците, фалопиевите тръби или първичен перитонеален карцином FIGO стадий I или IIA (степен 3 или само чиста клетъчна хистология; n = 142) или FIGO стадий IIB - IV (всички степени и всички хистологични типове, n = 1386) (NCI-CTCAE v.3).
BO17707 was a Phase III, two arm, multicentre, randomised, controlled, open-label study comparing the effect of adding Avastin to carboplatin plus paclitaxel in patients with FIGO stage I or IIA (Grade 3 or clear cell histology only; n = 142), or FIGO stage IIB - IV (all Grades and all histological types, n = 1386) epithelial ovarian, fallopian tube or primary peritoneal cancer following surgery (NCI- CTCAE v.3).
BO17929 е нерандомизирано клинично изпитване фаза ІІ с Perjeta, проведено при пациенти с метастазирал рак на гърдата, при които е настъпила прогресия по време на лечение с трастузумаб.
BO17929 was a phase II, non-randomised study in patients with metastatic breast cancer whose tumours had progressed during treatment with trastuzumab.
BO25341/SAWYER ще се разглеждат в текущ порядък.
B025341/SAWYER will be reviewed on an ongoing manner.
Bo3MO:J11-U 1-e:J1eIa1-U peaKlJUU
Take special care with Velosulin
Boceprevir 800 mg třikrát denně (atazanavir 300 mg/ritonavir 100 mg jednou denně)
Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
bod 4.3).
section 4.3).
Bodite posebno pozorni pri uporabi zdravila INOmax
Warnings and precautions
Bodite posebno pozorni pri uporabi zdravila PhotoBarr
Take special care with PhotoBarr
Bodite posebno pozorni pri uporabi zdravila PhotoBarr:
Take special care with PhotoBarr
Bodite pozorni na resne neželene učinke
Look out for serious side effects
Bodite previdni, če jemljete kakršnakoli zdravila, ki vas pomirijo (imajo sedativni učinek) ali pijete alkohol.
Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol.
Bodite previdni, če jemljete naslednja zdravila:
Take care if you are taking the following medicines:
Boehringer Ingelheim (Лого)
Boehringer Ingelheim (Logo)
Boehringer Ingelheim (емблема)
Boehringer Ingelheim (logo)
Boehringer Ingelheim España S.A. Tel: +34 93 404 51 00
Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00
Boehringer Ingelheim España S.A. Tel: +34 93 404 58 00
Boehringer Ingelheim España S.A. Tel: +34 93 404 51 00
Boehringer Ingelheim International GmbH Binger Strasse 173,
Boehringer Ingelheim International GmbH Binger Strasse 173
Boehringer Ingelheim Italia S.p.A. Tel: + 39 02 535 51
Boehringer Ingelheim Italia S.p.A. Tel: +39 02 535 51
Boehringer Ingelheim Ltd.
United Kingdom Boehringer Ingelheim Ltd.
Boehringer Ingelheim Pharma GmbH & Co.KG Binger Strasse 173
Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173
Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialasTel: +370 37 473922
Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 37 473922
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Boehringer Ingelheim RCV GmbH & Co KG
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Boehringer Ingelheim RCV GmbH & Co KG, organizačná zložka
Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH & Co KG, Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH & Co KG Viena-Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCVGmbH & Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH & Co KG Viena – Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH & Co KG, organizačná zložka
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Boehringer Ingelheim RCV GmbH & Co KG, Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &Co KG Eesti filiaal
Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal
Boehringer Ingelheim RCV Pharma GmbH & Co KG Magyarországi Fióktelepe
Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe
Boehringer Ingelheim RCVGmbH & Co KG Lietuvos filialas
Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas
Boehringer Ingelheim Sp. z o.o.
Boehringer Ingelheim Sp.zo.o.
Boehringer Ingelheim, Lda.
Boehringer Ingelheim, Unipessoal, Lda.
Boehringer Ingelheim, Unipessoal Lda.
Boehringer Ingelheim, Unipessoal, Lda.
Boehringer-Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Австрия Име и адрес на производителите, отговорни за освобождаване на партидите
Boehringer-Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Austria Name and address of the manufacturer responsible for batch release
Bola preukázaná chemická a fyzikálna stálosť počas 30 hodín pri teplote do 25 ºC.
Chemical and physical stability has been demonstrated for 30 hours up to 25ºC.
BOLERO-2 (проучване CRAD001Y2301), рандомизирано, двойносляпо, многоцентрово фаза III проучване на комбинацията Afinitor + екземестан спрямо плацебо + екземестан е проведено при жени в постменопауза с позитивен за естрогенни рецептори, HER2/neu негативен авансирал карцином на млечната жлеза, с рецидив или прогресия на заболяването след предшестваща терапия с летрозол или анастрозол.
BOLERO-2 (study CRAD001Y2301), a randomised, double-blind, multicentre phase III study of Afinitor + exemestane versus placebo + exemestane, was conducted in postmenopausal women with oestrogen receptor-positive, HER2/neu negative advanced breast cancer with recurrence or progression following prior therapy with letrozole or anastrozole.
Bolest břicha
Abdominal pain
bolest hlavy bolest břicha
headache tummy pain (abdominal pain).
bolest na hrudi
chest pain
bolest na hrudi, malátnost (celkově se necítíte dobře), horečka
chest pain, malaise (generally feeling unwell), fever
Bolest žaludku (břicha)
Stomach (abdominal) pain
Bolest žaludku (břicha)
Stomach (abdominal) pain.
bolesti hlavy, závratě
headache, dizziness
bolesti ledvin
gait disturbance
bolesti ledvin
myopathy
Bolesť brucha
Abdominal pain
Bolesť hlavy
Headache
Bolezen s fistulami
Fistula Response
Bolezen žolčnika (glejte poglavje 4.4).
Gallbladder disease (see section 4.4).
bolezen, ki vpliva na belo možganovino resno obolenje s pojavom mehurjev na koži, ustih in spolovilih
disease affecting the white matter of the brain serious illness with blistering of the skin, mouth and genitals
Bolezni
Renal disorders
Bolezni dihal, prsnega koša in mediastinal- nega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinaln ega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic, and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, tThoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Skin and subcutaneous tissue disorders
Bolezni endokrinega sistema
Cardiac disorders
Bolezni endokrinega sistema
Endocrine disorders
Bolezni jeter, žolčnika
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepato-biliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorders
Bolezni kože in podkožja
Nervous system disorders
Bolezni kože in podkožja
Skin and subcutaneous tissue disorders
Bolezni krvi in limfatičnega sistema
Blood and lymphatic system disorders
Bolezni krvi in limfatičnega sistema
Blood and the lymphatic system disorders
Bolezni mišično- skeletnega sistema in vezivnega tkiva
Musculoskeletal and connective tissue disorders
Bolezni mišično- skeletnega sistema in vezivnega tkiva
Musculoskeletal, connective tissue and bone disorders
Bolezni mišično- skeletnega sistema, vezivnega tkiva in kosti
Musculoskeletal, connective tissue and bone disorders
Bolezni mišično- skeletnega sistema, vezivnega tkiva in kosti
Reproductive system and breast disorders
Bolezni prebavil
Gastrointestinal disorders
Bolezni prebavil
Psychiatric disorders
Bolezni roženice so znani neželeni učinki, povezani z uporabo zdravila Teysuno.
Corneal disorders are a known adverse reaction with Teysuno use.
Bolezni sečil
Renal and urinary disorders
Bolezni sečil
Renal Disorders
Bolezni sečil:
General disorders:
Bolezni sečil:
Renal and urinary disorders:
Bolezni srca in pljuč
Pulmonary or cardiac disorders
Bolezni živčevja
Hypoxiab,d Dyspnoeac
Bolezni živčevja
Nervous system disorders
Bolezni živčevja
System Organ Classa
Bolezni živčevja
Vascular disorders
Bolezni živčevja: občutite lahko otrplost, ščemenje, bolečino, nenormalne občutke, mišično oslabelost, tresenje ali imate gibalne težave.
Nerve disorder: you may feel numbness, tingling, pain, abnormal sensation, weak muscle, shaking, or movement difficulties.
Bolečina
Pain
bolečina v jetrih, zvišana gama-glutamiltransferaza
Hepatic pain, gammaglutamyl transferase increased.
bolečina v prsih ali srčna kap, visok ali nizek krvni tlak, nelagodje v prsnem košu.
chest pain or heart attack, high blood pressure or low blood pressure, chest discomfort
Bolečina, rdečina, otekanje ali rane v vaših ustih Slabost
Pain, redness, swelling or sores in your mouth Nausea
Bolečine v prsnem košu.
Chest pain.
bolečine v sklepih nenormalnosti elektrokardiograma (podaljšanje intervala QT)
joint pain electrocardiogram abnormalities (QT prolongation)
bolečine v trebuhu (želodcu)
abdominal (stomach) pain
Bolečine v ustih, zobeh in/ali čeljustih, oteklost ali neceljenje ran v ustni votlini ali čeljusti, izcedek, odrevenelost ali občutek teže v čeljusti ali majanje zoba.
Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth.
Bolnica topotekana ne sme prejeti, če število nevtrofilcev ni večje ali enako 1,5 x 109/l, število trombocitov večje ali enako 100 x 109/l in vrednost hemoglobina večja ali enaka 9 g/dl (po transfuziji, če je le-ta potrebna).
1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9 g/dl (after transfusion if necessary).
Bolnice brez predhodne kemoterapije s cisplatinom
Patients without Prior Cisplatin Chemoradiotherapy
Bolnice s predhodno kemoterapijo s cisplatinom
Patients with Prior Cisplatin Chemoradiotherapy
Bolnice so bile enakomerno razdeljene v skupino, ki je prejemala zoledronsko kislino, in skupino, ki je prejemala placebo.
Patients were evenly distributed between zoledronic acid-treated and placebo groups.
Bolnice so eno leto na štiri tedne dobivale bodisi 4 mg zoledronske kisline bodisi placebo.
Patients received either 4 mg zoledronic acid or placebo every four weeks for one year.
Bolnik dobi najmanjši odmerek, ki je še učinkovit.
The lowest effective dose will be sought.
Bolnik lahko zdravilo vzame s hrano ali brez nje.
It may be given with or without food.
Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
A patient with poor metaboliser status will possess two loss-of-function alleles as defined above.
Bolnike in negovalce je treba poučiti o možnem pojavu manije in delirija med zdravljenjem s pramipeksolom.
Patients and carers should be made aware that mania and delirium can occur in patients treated with pramipexole.
Bolnike je potrebno poučiti o tem, da se PhotoBarr zadržuje v telesu 60-90 dni po injekciji. se PhotoBarr aktivira z vidno svetlobo.
Remains in your body for 60-90 days after receiving the injection
Bolnike je treba nanje opozoriti in jim svetovati, naj bodo med zdravljenjem z zdravilom Pramipeksol Accord pri vožnji in upravljanju strojev previdni.
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with Pramipexole Accord.